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Abstract 
Objectives 
Ureteral obstruction is one of the complications of testicular tumor with 
retroperitoneal lymph node (RPLN) metastasis that requires ureteral stenting for 
management. We elucidated the clinical courses of ureteral obstructions and 
changes in renal functions in patients with indwelling ureteral stenting. 
Patients and Methods 
The medical records of 56 patients who were treated for metastatic 
testicular tumors by chemotherapy at a single institute between 2002 to 2010 
were retrospectively reviewed. 
Results 
Among 56 patients, 12 patients needed ureteral stenting before 
chemotherapy. The proportion of patients requiring ureteral stenting was 
significantly higher in seminoma than non-seminoma (47% and 12%, 
respectively, P<0.05). The ureteral stent was removed after chemotherapy or 
retroperitoneal lymph node dissection (RPLND) in all patients, except for one 
patient who died of cancer during chemotherapy. At RPLND, ureters were 
spared in three patients, a partial ureterectomy was needed in one patient, and 
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no case underwent adjunctive nephrectomy. These 11 patients presented no 
local and distant recurrence at median follow-up of 44 months. Ureteral stenting 
increased the estimated glomerular filtration rate to more than 60 ml/min before 
chemotherapy in all patients, but it decreased to less than 60 ml/min in six of 11 
patients after chemotherapy. 
Conclusion 
Ureteral obstruction due to testicular tumor was relieved after 
chemotherapy or RPLND. Ureteral stenting was effective to improve renal 
function before chemotherapy, although we should pay special attention to 
deterioration of renal function during or after chemotherapy.  
 
Mini abstract 
The ureteral stenting is effective to manage the hydronephrosis of 
metastatic testicular tumor patients. But, attention should be paid to deterioration 
of renal function during or after chemotherapy.  
 
Key words: ureteral stent, testicular tumor, retroperitoneal lymph node 
(RPLN), hydronephrosis, chemotherapy 
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Introduction 
Testicular tumor is one of the common malignancies in young men and is 
well known as a rapidly progressive disease. Between 1980 and 1990, effective 
chemotherapy regimens including cisplatin against advanced testicular tumors 
were established. These chemotherapies and surgical interventions like 
retroperitoneal lymph node dissection (RPLND) achieved a high cure rate even 
in patients with multiple metastases. On the other hand, intensive 
chemotherapy with or without surgical treatment leads to several late sequelae 
in long-term testicular cancer survivors, and persistently impaired renal function 
is one of them (1-3).  
The retroperitoneal lymph node (RPLN) is a common site of metastasis 
in advanced testicular tumors, and large metastases in RPLN occasionally lead 
to ureteral obstruction and resultant hydronephrosis (4,5). Ureteral obstruction 
and the resultant hydronephrosis may cause renal impairment and urinary tract 
infection during chemotherapy. Importantly, renal impairment limits delivery of 
adequate doses of anticancer drugs including cisplatin, which might result in a 
lower cure rate. Therefore, effective interventions to prevent ureteral obstruction 
are recommended in management of advanced testicular tumor (6). 
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Retrograde ureteral stenting is the most widely used initial treatment for 
malignant ureteral obstruction. Several investigators have described the efficacy 
and limitations of ureteral stenting for extrinsic ureteral obstruction due to pelvic 
malignancies such as gynecological cancer and colon cancer (7-9). These 
malignancies with ureteral obstruction due to metastasis are not curable, and 
generally ureteral obstruction progression follows disease progression. In 
contrast, ureteral obstruction should be relieved in patients with testicular tumor 
because most patients with advanced testicular tumor can be cured. However, 
the safety and efficacy of ureteral stenting during chemotherapy for advanced 
testicular tumor has not been well described. Also, it is not clear what proportion 
of patients can be stent-free after chemotherapy or will need adjunctive 
nephrectomy at RPLND due to resection of the ureter involved.  
In this retrospective study, we reviewed our clinical experience with 
ureteral stenting in patients with advanced testicular tumor to elucidate how to 
manage ureteral obstruction and also examine the impact of ureteral stenting on 
renal function during and after chemotherapy. 
 
Materials and Methods  
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Patients 
A total of 56 advanced germ cell tumor patients were treated at Tsukuba 
University Hospital between June 2002 and August 2010. We retrospectively 
reviewed charts of these patients and identified 12 patients who underwent 
ureteral stenting for extrinsic ureteral obstruction due to retroperitoneal mass 
(Table 1). The median age at diagnosis was 39 years (range 26–58 years). They 
included 11 testicular tumor patients with RPLN metastasis and one 
retroperitoneal germ cell tumor patient. In 11 patients, retrograde ureteral 
stenting was performed before the start of chemotherapy. In the remaining 
non-seminoma patient, percutaneous nephrostomy (PCN) was initially required 
due to the inability to place a ureteral stent, but a ureteral stent was successfully 
placed after four courses of chemotherapy. A ureteral stent was placed in the left 
kidney in eight patients and the right kidney in five patients. One patient needed 
bilateral ureteral stenting. 
 
Treatment for testicular tumors 
Ten patients received a protocol consisting of bleomycin, etoposide, and 
cisplatin (BEP) (10) as the induction chemotherapy. Two patients who had risk 
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factors for bleomycin pneumonitis were treated with four courses of etoposide 
and cisplatin (EP). Dose reduction due to renal dysfunction was needed in four 
of 39 courses of induction chemotherapy. Postponements in the start of 
chemotherapy were observed in six of 27 subsequent treatment courses. The 
median duration of postponement was three days (1–6 days). In addition to the 
induction chemotherapy, six patients received second line or salvage 
chemotherapy for refractory or relapsed disease. The most frequently used 
second line chemotherapy regimen was paclitaxel, ifosfamide, and cisplatin 
(TIP) (11). Three patients needed a third line or further chemotherapy.  
Principally, non-seminoma patients underwent surgical resection of residual 
operable masses when all tumor markers had normalized. However, surgery 
was omitted in seminoma patients with an adequately responding RPLN mass 
(less than 3 cm in diameter or negative FDG-PET scan), and they were followed 
closely. One non-seminoma patient underwent salvage RPLND under a tumor 
marker-positive and chemo-refractory condition. 
 
Indication for and management of ureteral stenting 
In principle, we adapted ureteral stenting when significant hydronephrosis 
8 
 
due to ureteral obstruction was identified. During chemotherapy, the ureteral 
stent was exchanged at least once every three months. At each ureteral stent 
exchange, retrograde pyelography was performed to assess ureteral obstruction. 
When ureteral obstruction was relieved, the ureteral stent was removed. In 
patients who underwent RPLND, the ureteral stent was removed after recovery 
from surgery. 
 
Evaluation of renal function 
   The glomerular filtration rate (GFR) was estimated based on the serum 
creatinine concentration using the formula reported by Matsuo et al. (12). This 
equation originated from the Modification of Diet in Renal Disease (MDRD) study 
group (13), designed for Japanese individuals and recommended by the 
Japanese Society of Nephrology: eGFR (ml/min/1.73m2) = 194 x serum Cr-1.094 x 
age (years)-0.287. 
 
Statistical analysis 
 Differences in patient age and RPLN mass size between groups were 
analyzed by Student's t-test. Chi-square analysis was performed to compare 
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histology, risk category, and the proportions of seminoma and non-seminoma 
patients who underwent ureteral stenting. Pre-treatment eGFR were compared 
during and after treatment using 1-factor repeated measures ANOVA. A value of 
P<0.05 was considered statistically significant. Statistical analysis was 
performed using JMP software (version 9.02; SAS Institute Inc., Cary, NC) 
 
Results 
Factors related to ureteral stenting 
Among 56 patients (14 seminoma and 42 non-seminoma) treated for 
metastasis of testicular tumors, ureteral stenting was performed on 12 patients 
before chemotherapy. As shown in Table 1, the proportion of patients with 
ureteral stenting was significantly higher in seminoma than in non-seminoma 
(47% and 12%, respectively, P<0.05). As for risk classification, all seven 
seminoma patients were classified as having a good prognosis according to the 
International Germ Cell Consensus Classification Group (IGCCCG) criteria (14), 
whereas four of five non-seminoma patients (80%) were classified into the 
intermediate or poor prognosis group. The median RPLN size of 12 patients was 
significantly greater than that of 31 patients having RPLN metastases and 
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treated without ureteral stenting (8.4 cm and 4.0cm, respectively: P<0.05).There 
was no significant difference in age or IGCCCG category distribution. 
 
Clinical course for ureteral obstruction 
 There were no episodes of stent failure such as worsening 
hydronephrosis or inability to replace stent during stent replacement procedure. 
One patient developed the definite upper urinary tract infection, which could be 
managed with broad-spectrum antibiotics. During chemotherapy, two 
complications directly related to ureteral stent were observed. One was 
intraureteral migration, which needed ureteroscopy for removal.  Another was 
fistula formation between ureter and necrotized lymph node mass. In the case, 
partial ureterectomy was performed in combined with RPLND.  
In all seven seminoma patients, the ureteral stent was removed after 
chemotherapy (Table 2). The ureteral stent was removed after induction 
chemotherapy in six patients, and after salvage chemotherapy in the remaining 
seminoma patient. In contrast, the ureteral stent could not be removed after 
chemotherapy in non-seminoma patients. However, the ureteral stent was 
removed after RPLND in four of five non-seminoma patients. The remaining 
non-seminoma patient died of cancer without marker normalization and without 
removal of the ureteral stent.  
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During RPLND, the ureter was spared in three patients, and partial 
ureterectomy was needed in one patient, who had developed a fistula between 
the ureter and a necrotized lymph node mass during chemotherapy. There were 
no cases needing adjunctive nephrectomy at RPLND. As for the pathological 
findings at RPLND, no residual germ cell cancer or teratoma element was 
identified in three patients, and a few foci of adenocarcinoma in a residual 
teratoma were identified in a patient who underwent RPLND with alpha 
fetoprotein (AFP)-positive status. In all four patients, no adjuvant chemotherapy 
was performed after RPLND. These 11 patients continued with no evidence of 
disease at a median follow-up of 44 months (range 6 to 97 months). 
 
Change of renal functions during and after treatment 
Ureteral stenting tended to increase the median eGFR from 68.3 ml/min to 
82.5 ml/min, although the difference was not statistically significant (Figure 1). 
Importantly, three patients presented insufficient renal function for chemotherapy 
including cisplatin (less than 60 ml/min eGFR), and ureteral stenting improved 
eGFR to more than 60 ml/min in these three patients before chemotherapy. On 
the other hand, chemotherapy decreased eGFR significantly (P=0.016), and the 
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eGFR was below 60 ml/min in six of 11 patients after treatment. However, no 
further deterioration in eGFR was observed at one year after the last treatment. 
To identify the factors related to deterioration of renal functions, we 
compared patient profiles, treatment procedures, and CT findings at the last 
follow-up of patients with eGFR above and below 60 ml/min after treatment 
(Table 3). The CT findings of the kidney at the last follow up were normal in all 
patients whose eGFR was above 60 ml/min. In contrast, persistent 
hydronephrosis or apparent kidney atrophy was observed in five of six patients 
whose eGFR was below 60 ml/min. There were no significant differences in age, 
histology, chemotherapy courses, and history of RPLND between each group. 
 
 
Discussion 
Once inserted, a ureteral stent or PCN usually becomes permanent in 
patients with advanced cancers other than testicular tumor because they are not 
curable (7-9). On the other hand, most advanced testicular tumors can be cured 
by chemotherapy and surgery. Therefore, sparing the involved kidney and 
preservation of renal function are important clinical goals. However, to our 
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knowledge, there has been no report focused on the outcome of ureteral stent 
management during chemotherapy for testicular tumor. In the present 
retrospective study, we showed that ureteral stenting effectively improved renal 
function, which allowed completion of chemotherapy with adequate drug 
intensity.  Second, we showed that involved ureters can be spared in most 
cases without worsening the oncological outcome. 
The incidences of hydronephrosis in advanced seminoma and 
non-seminoma were reported to be about 25% and 35%, respectively (4, 5). In 
our series, ureteral stenting was needed in 21% of advanced testicular tumor 
patients, especially in the patients with a larger RPLN mass (median diameter of 
8.4 cm). The proportion of ureteral stenting in seminoma was 45% in our series, 
and higher than previous reports (4). This might be a result of selection bias 
since most seminoma patients were initially diagnosed at community hospitals 
and referred to our hospital for treatment of advanced disease.  
In the present study, all seminoma patients were cured by chemotherapy, 
and the stent could be removed in all cases after chemotherapy alone. In 
contrast, all non-seminoma patients underwent RPLND after chemotherapy, 
except one patient who died of the disease during chemotherapy. At RPLND, the 
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involved ureter was spared in three patients, and partial ureterectomy was 
needed in the remaining one. The ureteral stent could be removed in all patients 
after RPLND. It is important to estimate the risk of residual viable cancer around 
the involved ureter and to decide whether involved ureters can be spared or 
resected adjunctively at RPLND. Nash et al. reported that en block nephrectomy 
was performed at RPLND in 19% of post-chemotherapy non-seminoma patients 
(15). Stephenson et al. reported that adjunctive nephrectomy was necessary in 
53% of non-seminoma patients with risk factors for residual viable cancer. The 
proposed risk factors for adjunctive nephrectomy include post-salvage 
chemotherapy, desperation RPLND, late relapse, and reoperative RPLND (16). 
In the present study, pathological examination of RPLND specimens revealed 
only necrotic tissue in three of four patients. The other patient, who underwent 
desperation RPLND with elevated AFP, had a teratoma with malignant 
transformation, but the surgical margin was negative. There was no recurrence 
after RPLND in all patients. We consider kidney-sparing surgery possible in 
selected cases with attention to the surgical margin.  
The primary purpose of ureteral stenting is safe delivery of chemotherapy 
and preservation of renal function during chemotherapy. In our data, ureteral 
15 
 
stenting improved eGFR to more than 60 ml/min in all patients. As a result, 
induction chemotherapy was possible without dose reduction in 90% of 
treatment courses. The drug intensity of the induction chemotherapy was similar 
to that of our previous study (17). However, eGFR decreased significantly to 
below 60 ml/min in six of 11 patients after chemotherapy even if ureteral 
obstruction was treated with ureteral stenting.  
Previous studies have demonstrated a 20–30% reduction in the GFR in 
long-term follow up after chemotherapy for testicular tumor (18). Age at 
treatment and the type of treatment were associated with renal impairment (2). 
We previously reported that patients who developed renal impairment during 
chemotherapy might be at risk of further elevation of serum creatinine during 
long-term follow up (19). In the present series, the follow-up CT revealed 
progressive renal atrophy in three cases and persistent mild hydronephrosis in 
three cases in the patients whose eGFR fell below 60 ml/min. The patient age, 
histological type, number of courses of chemotherapy, and undergoing of 
RPLND were not associated with eGFR after chemotherapy. The severity of 
hydronephrosis might be associated with the renal impairment, but we could not 
adequately grade hydronephrosis in the present retrospective study.  
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Testicular tumor is highly curable cancer; therefore, assessment of the 
long-term morbidity is important due to the life expectancy of this group of young 
men (3). The morbidity includes secondary malignant neoplasms, neuropathy, 
gonadal dysfunction, nephrotoxicity, and cardiovascular disease. The latter two 
morbidities may be associated because a large population-based study showed 
a graded association between a reduced eGFR and the risk of cardiovascular 
events (20). To avoid post-treatment eGFR reduction, it is a reasonable to treat 
advanced testicular tumor patients with the intention of sparing the kidneys when 
possible. 
In conclusion, Ureteral obstruction due to testicular tumor was relieved after 
chemotherapy or RPLND in most of cases. Ureteral stenting was effective to 
improve renal function before chemotherapy, although we should pay special 
attention to deterioration of renal function during or after chemotherapy.  
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Figure legend 
Figure 1   Changes in eGFR in each patient 
The eGFR during treatment of each patient who needed ureteral stenting is 
plotted. The treatment for seminoma patients was chemotherapy. For 
non-seminoma patients, treatment was chemotherapy and RPLND. Note that a 
significant decrease in eGFR was observed after treatment despite ureteral 
stenting.  
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